EATONTOWN, N.J., July 31 /PRNewswire/ -- Roberts Pharmaceutical
Corporation (Amex: RPC) today announced it reached an agreement in principle
to settle the shareholder class action that had been instituted in April 1995
against it and certain of its current and former officers on behalf of certain
shareholders of the Company.
    The agreement provides for a single payment of $6 million to members of
the class, funded in major part by the Company's insurance carrier.  The
net expense of the settlement to Roberts will amount to approximately
$1.8 million, before taxes, and will be recorded as a non-operating, one-time
charge in the third-quarter of 1997.  However, even after including this
non-recurring charge, the third-quarter of 1997 currently appears to be on
track towards becoming the Company's fourth consecutive quarter of
profitability.
    "The Company believes it complied with all its obligations under the
Federal securities laws and that the plaintiff's allegations are without
merit," said Dr. Robert A. Vukovich, Chairman and CEO of Roberts.
"Nevertheless, Roberts has agreed to settle this class action to avoid further
costly litigation and alleviate further earnings pressure associated with
those expenses."  He continued by noting, "With the recent launches of
our first two pipeline products and the purchase of a manufacturing facility,
we have achieved important goals in positioning Roberts for growth as a fully
integrated pharmaceutical company.  Settlement of the class action will allow
us to focus management's energy as well as our financial resources on the
Company's future growth."
    Roberts Pharmaceutical Corporation, with operating subsidiaries in the
United States, Canada, and the United Kingdom, focuses on new health care
solutions through the acquisition and development of specialty
pharmaceuticals.  The Company's first pipeline product, ProAmatine(R), was
recently launched in the U.S. as the first FDA cleared drug to treat
orthostatic hypotension.  Agrylin(TM), Roberts' second pipeline product, has
since been launched in the U.S. as the first drug cleared to treat essential
thrombocythemia and is currently under review for approval in Canada and the
European Union.
    This and past press releases of Roberts Pharmaceutical Corporation are
available through PR Newswire's Company News On-Call fax service at
1-800-758-5804, extension 760975 and on the Internet at
http://www.prnewswire.com and http://www.robertspharm.com.
    This release may contain forward-looking statements which reflect
management's current views of future events and operations.  These forward-
looking statements are based on assumptions and external factors, including
assumptions relating to regulatory action and competing products.  Any changes
in such assumptions or external factors could produce significantly different
results.

Link to this page: